LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LBRX LB Pharmaceuticals Inc

交易中 03-02 10:24:48 EST

22.76

-1.25

-5.21%

最高24.02	最低22.20	成交量3.07万
今开23.55	昨收24.01	日振幅7.58%
总市值6.51亿	流通市值4.32亿	总股本2,861万
成交额71.55万	换手率0.16%	流通股本1,900万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals Inc","latestPrice":22.76,"timestamp":1772465085004,"preClose":24.01,"halted":0,"volume":30678,"delay":0,"changeRate":-0.052061640982923776,"floatShares":19000000,"shares":28605700,"eps":-0.743267,"marketStatus":"交易中","change":-1.25,"latestTime":"03-02 10:24:48 EST","open":23.55,"high":24.02,"low":22.2,"amount":715466.425824,"amplitude":0.075802,"askPrice":22.78,"askSize":5,"bidPrice":22.61,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-0.743267,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":24.01,"preHourTrading":{"tag":"盘前","latestPrice":24.01,"preClose":24.01,"latestTime":"09:15 EST","volume":5960,"amount":143099.6,"timestamp":1772460939420,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.01,"preClose":24.01,"latestTime":"16:18 EST","volume":2330,"amount":55946.803,"timestamp":1772227104405,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.733104},"requestUrl":"/m/hq/s/LBRX","defaultTab":"news","newsList":[{"id":"1124088225","title":"LB制药宣布完成1亿美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1124088225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124088225?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:11","pubTimestamp":1770297074,"startTime":"0","endTime":"0","summary":"纽约，2026年2月5日——专注于开发精神分裂症、双相抑郁等神经精神疾病创新疗法的后期生物制药公司LB Pharmaceuticals Inc今日宣布，已与特定机构投资者签署证券购买协议，通过私募方式发行3,306,571股普通股及可认购最多1,417,107股普通股的预融资权证。普通股发行价为每股21.17美元，预融资权证发行价为每股21.1699美元。在扣除交易费用前，本次私募预计可为公司筹集约1亿美元总收益，交易预计于2026年2月6日左右完成，最终需满足惯例交割条件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4213","LB","BK4007","BK4233"],"gpt_icon":0},{"id":"1167670995","title":"LB Pharmaceuticals启动双相抑郁症II期Illuminate-1试验 拓展LB-102研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1167670995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167670995?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:02","pubTimestamp":1769432543,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals近日正式启动针对双相抑郁症的II期临床试验Illuminate-1，标志着其核心候选药物LB-102的研发版图实现重要拓展。该试验旨在评估LB-102在双相抑郁患者中的疗效与安全性，为这一难治性精神疾病提供潜在创新疗法。\nIlluminate-1试验的推进不仅深化了LB-102的临床开发路径，更彰显了公司对精神神经疾病治疗领域的战略聚焦。通过阶段性临床试验数据的积累，LB Pharmaceuticals有望进一步验证该药物的治疗潜力，为后续研发决策提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2604391875","title":"Lb Pharmaceuticals Inc盘中异动 早盘急速下挫5.22%报20.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604391875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604391875?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:17","pubTimestamp":1768580279,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日00时17分，Lb Pharmaceuticals Inc股票出现异动，股价大幅跳水5.22%。截至发稿，该股报20.27美元/股，成交量4.6651万股，换手率0.18%，振幅6.20%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.12%。Lb Pharmaceuticals Inc公司简介：LB Pharmaceuticals Inc 是一家临床阶段生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1104130764","title":"LB制药强化领导团队，企业事务及人力与文化部门迎来关键任命","url":"https://stock-news.laohu8.com/highlight/detail?id=1104130764","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104130764?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:01","pubTimestamp":1767700876,"startTime":"0","endTime":"0","summary":"LB制药近日宣布对其领导团队进行重要人事调整，在企业事务及人力与文化部门任命了关键高管，以进一步巩固公司的管理架构。\n此次任命旨在加强公司内部治理与人才发展战略，通过引入资深管理人才提升组织效能。新任命的高管将负责推动企业文化建设、人才发展体系优化以及内外部沟通策略的完善。\n公司表示，这一系列人事变动将有助于提升企业运营效率，为未来的业务拓展奠定坚实基础。通过强化领导团队，LB制药展现出对组织发展与人才战略的高度重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"1159324610","title":"新闻稿：LB Pharmaceuticals根据纳斯达克上市规则5635(c)(4)向新员工授予诱因奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1159324610","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159324610?lang=zh_cn&edition=full","pubTime":"2025-12-11 06:09","pubTimestamp":1765404561,"startTime":"0","endTime":"0","summary":"纽约，2025年12月10日—— LB Pharmaceuticals Inc今天宣布，公司已向新的首席商业官Kaya Pai Panandiker授予一项股权奖励，该奖励超出但需遵循LB Pharmaceuticals Inc 2025年股权激励计划的条款与条件。该股权奖励于2025年12月10日授予，依据纳斯达克上市规则5635中提供的“诱因授予”例外，旨在作为Pai Panandiker女士进入LB Pharmaceuticals工作的诱因。Pai Panandiker女士获得了以21.36美元的行使价格购买195,000股LB Pharmaceuticals普通股的期权，行使价格为授予日LB Pharmaceuticals普通股的收盘价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","NQmain","BK4213","BK4233","BK4007","LBRX"],"gpt_icon":0},{"id":"2582192310","title":"Lb Pharmaceuticals Inc盘中异动 大幅上涨5.48%报15.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582192310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582192310?lang=zh_cn&edition=full","pubTime":"2025-11-12 01:01","pubTimestamp":1762880496,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日01时01分，Lb Pharmaceuticals Inc股票出现异动，股价大幅拉升5.48%。截至发稿，该股报15.41美元/股，成交量1.6191万股，换手率0.06%，振幅5.70%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为1.30%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc.、天演药业涨幅较大，Quoin Pharmaceuticals Ltd、Salarius Pharmaceuticals, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为2759.59%、389.11%、370.59%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.，振幅分别为75.38%、58.48%、54.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112010136a6f271fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112010136a6f271fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"1172318551","title":"LB Pharmaceuticals Inc - 预计现有现金、现金等价物和可交易证券能够支持计划运作至2028年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1172318551","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172318551?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:14","pubTimestamp":1762434867,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc - 预计现有现金、现金等价物和可交易证券能够支持计划运作至2028年第二季度","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1143506269","title":"LB Pharmaceuticals任命William Kane和Rekha Hemrajani加强董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1143506269","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143506269?lang=zh_cn&edition=full","pubTime":"2025-09-25 20:31","pubTimestamp":1758803516,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals宣布通过任命William Kane和Rekha Hemrajani两位新成员来加强其董事会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1124155235","title":"异动解读 | LB制药（LBRX）美股上市首日盘中大涨90%，新药研发前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1124155235","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124155235?lang=zh_cn&edition=full","pubTime":"2025-09-12 00:14","pubTimestamp":1757607260,"startTime":"0","endTime":"0","summary":"生物科技公司LB制药今日在美国股市上市交易，盘中股价大涨90%，引发市场高度关注。该公司专注于开发治疗神经精神疾病的药物，其首次公开发行价格为15美元。LB制药的主打产品是一种名为LB-102的口服小分子药物，主要用于治疗急性精神分裂症。公司计划于2026年第一季度开始LB-102的三期临床试验。这一进展表明LB制药在神经精神疾病治疗领域具有巨大潜力，投资者对公司的发展前景持乐观态度。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LBRX"],"gpt_icon":0},{"id":"2566531990","title":"美股异动 | LB Pharmaceuticals(LBRX.US)登陆美股市场 开盘涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566531990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566531990?lang=zh_cn&edition=full","pubTime":"2025-09-12 00:03","pubTimestamp":1757606604,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LBRX","LB","BK4213","BK4233","BK4134","159837","III"],"gpt_icon":0},{"id":"2566958325","title":"LB Pharmaceuticals IPO定价15美元/股，今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2566958325","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566958325?lang=zh_cn&edition=full","pubTime":"2025-09-11 11:53","pubTimestamp":1757562824,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，致力于开发神经精神疾病药物的生物科技公司LB Pharmaceuticals周三表示，其在美国首次公开募股中筹集了2.85亿美元，这是2月以来规模最大的生物科技IPO。此次IPO对LB Pharmaceuticals的估值为3.015亿美元。在由高增长、科技型公司主导的IPO市场中，LB Pharmaceuticals的上市意味着生物科技IPO走出寒冬。LB Pharmaceuticals明确意识到了这一挑战。LB Pharmaceuticals预计将于2026年第一季度开始III期临床试验。LB Pharmaceuticals将于周四在纳斯达克上市，股票代码为“LBRX”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LB Pharmaceuticals IPO定价15美元/股，今晚登陆纳斯达克","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LBRX"],"gpt_icon":0},{"id":"2566661519","title":"生物科技IPO“解冻”！LB Pharmaceuticals(LBRX.US)IPO定价14-16美元/股，拟筹资2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566661519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566661519?lang=zh_cn&edition=full","pubTime":"2025-09-09 15:04","pubTimestamp":1757401462,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，致力于开发神经精神疾病药物的生物科技公司LB Pharmaceuticals周一公布了IPO定价条款。按照拟议发行价区间的中点计算，LB Pharmaceuticals市值将达到3.015亿美元。LB Pharmaceuticals预计将打破10多年来最长的生物科技IPO寒冬，成为自2025年2月Aardvark Therapeutics上市后首个规模较大的生物科技IPO。LB Pharmaceuticals预计将于2026年第一季度开始III期临床试验。LB Pharmaceuticals成立于2015年，计划在纳斯达克上市，股票代码为“LBRX”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4233","159837","LBRX","BK4213","LB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lbpharma.us","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":0.1304},{"period":"3month","weight":0.3496},{"period":"6month","weight":0.6007},{"period":"ytd","weight":0.0786}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LB Pharmaceuticals Inc于2015年9月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新疗法。","exchange":"NASDAQ","name":"LB Pharmaceuticals Inc","nameEN":"LB Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"LB Pharmaceuticals Inc,LBRX,LB Pharmaceuticals Inc股票,LB Pharmaceuticals Inc股票老虎,LB Pharmaceuticals Inc股票老虎国际,LB Pharmaceuticals Inc行情,LB Pharmaceuticals Inc股票行情,LB Pharmaceuticals Inc股价,LB Pharmaceuticals Inc股市,LB Pharmaceuticals Inc股票价格,LB Pharmaceuticals Inc股票交易,LB Pharmaceuticals Inc股票购买,LB Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}